Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

Summary

Hematologic improvement of erythrocytes after 6 months of canakinumab treatment.

Timeline

Start

2022-04-26

Primary completion

2024-02-29

Completion

2024-02-29

Outcome

Outcome not reported

Stopped (Enrollment): “Slow recruitment. It is not considered likely that the CANFIRE trial will be able to reach the target number of patients. Clinical responders will be further treated within the trial (expected duration: 3 years after stop of enrollment).”

Drugs

Indications